Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

August 2011 - FRMC

08/22/2011
Chicago—A study of patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who had previously used ketoconazole and then took abiraterone acetate showed that the 2 drugs could be used as sequential therapy. The...
Chicago—A study of patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who had previously used ketoconazole and then took abiraterone acetate showed that the 2 drugs could be used as sequential therapy. The...
Chicago—A study of patients with...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—An analysis of a diabetes simulation model from a US healthcare payer perspective found that patients with type 2 diabetes taking premixed insulin analogs were likely to have increased life expectancy and quality-adjusted life...
San Diego—An analysis of a diabetes simulation model from a US healthcare payer perspective found that patients with type 2 diabetes taking premixed insulin analogs were likely to have increased life expectancy and quality-adjusted life...
San Diego—An analysis of a...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—A pooled analysis of three phase 3, placebo-controlled, randomized trials found that patients with type 2 diabetes and poor glycemic control who took linagliptin for 24 weeks had a statistically significant reduction in hemoglobin...
San Diego—A pooled analysis of three phase 3, placebo-controlled, randomized trials found that patients with type 2 diabetes and poor glycemic control who took linagliptin for 24 weeks had a statistically significant reduction in hemoglobin...
San Diego—A pooled analysis of...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—The annual costs associated with managing patients with type 2 diabetes through a structured lifestyle intervention decreased during a 4-year period, according to results of an ongoing multicenter, randomized controlled trial. Ping...
San Diego—The annual costs associated with managing patients with type 2 diabetes through a structured lifestyle intervention decreased during a 4-year period, according to results of an ongoing multicenter, randomized controlled trial. Ping...
San Diego—The annual costs...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—Patients with type 2 diabetes who switched from taking sitagliptin to liraglutide showed improvements in glycemic control and weight loss after 26 weeks. In addition, the percentage of patients achieving an ADA target hemoglobin A1c...
San Diego—Patients with type 2 diabetes who switched from taking sitagliptin to liraglutide showed improvements in glycemic control and weight loss after 26 weeks. In addition, the percentage of patients achieving an ADA target hemoglobin A1c...
San Diego—Patients with type 2...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—Patients with type 2 diabetes who underwent an intensive dietary intervention showed significant improvement in glycemic control compared with those who received normal care. However, among the patients who had the diet...
San Diego—Patients with type 2 diabetes who underwent an intensive dietary intervention showed significant improvement in glycemic control compared with those who received normal care. However, among the patients who had the diet...
San Diego—Patients with type 2...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—A retrospective analysis of an electronic medical record database found that patients with type 2 diabetes who were receiving a glucose-lowering therapy and then added twice-daily injections of exenatide to their regimen had an...
San Diego—A retrospective analysis of an electronic medical record database found that patients with type 2 diabetes who were receiving a glucose-lowering therapy and then added twice-daily injections of exenatide to their regimen had an...
San Diego—A retrospective...
08/22/2011
First Report Managed Care
08/22/2011
During the ADA meeting, a pharmaceutical industry executive and an FDA official provided their views on the pharmaceutical industry.
During the ADA meeting, a pharmaceutical industry executive and an FDA official provided their views on the pharmaceutical industry.
During the ADA meeting, a...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—A phase 3b trial presented in a poster session at the ADA meeting indicated that adult patients with type 2 diabetes who took 5 mg of saxagliptin once daily as an add-on therapy to insulin (with or without metformin) showed greater...
San Diego—A phase 3b trial presented in a poster session at the ADA meeting indicated that adult patients with type 2 diabetes who took 5 mg of saxagliptin once daily as an add-on therapy to insulin (with or without metformin) showed greater...
San Diego—A phase 3b trial...
08/22/2011
First Report Managed Care
08/22/2011
San Diego—An open-label, randomized trial found that patients with type 2 diabetes who took insulin degludec in a flexible regimen had similar glycemic control, rates of hypoglycemia, insulin dose, and weight gain compared with patients who...
San Diego—An open-label, randomized trial found that patients with type 2 diabetes who took insulin degludec in a flexible regimen had similar glycemic control, rates of hypoglycemia, insulin dose, and weight gain compared with patients who...
San Diego—An open-label,...
08/22/2011
First Report Managed Care

Advertisement

Advertisement

Advertisement